Rhythm Pharmaceuticals Inc Asset Resilience Ratio
Rhythm Pharmaceuticals Inc asset resilience ratio. Rhythm Pharmaceuticals Inc (RYTM) has an Asset Resilience Ratio of 69.55% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Rhythm Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Rhythm Pharmaceuticals Inc (2012–2025)
Asset resilience ratio of Rhythm Pharmaceuticals Inc from 2012 to 2025. This chart shows how Rhythm Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See financial agility of Rhythm Pharmaceuticals Inc to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Rhythm Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Rhythm Pharmaceuticals Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $334.65 Million | 69.55% |
| Total Liquid Assets | $334.65 Million | 69.55% |
Asset Resilience Insights
- Very High Liquidity: Rhythm Pharmaceuticals Inc maintains exceptional liquid asset reserves at 69.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rhythm Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Rhythm Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Rhythm Pharmaceuticals Inc Asset Resilience Ratio by Year (2012–2025)
Rhythm Pharmaceuticals Inc asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Rhythm Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 69.55% | $334.65 Million | $481.19 Million | +10.55pp |
| 2024-12-31 | 59.00% | $231.43 Million | $392.27 Million | -5.85pp |
| 2023-12-31 | 64.84% | $215.76 Million | $332.75 Million | +11.09pp |
| 2022-12-31 | 53.76% | $205.61 Million | $382.48 Million | -17.74pp |
| 2021-12-31 | 71.50% | $235.61 Million | $329.52 Million | +33.04pp |
| 2020-12-31 | 38.45% | $71.94 Million | $187.07 Million | -36.15pp |
| 2019-12-31 | 74.60% | $230.16 Million | $308.52 Million | -3.23pp |
| 2018-12-31 | 77.83% | $202.52 Million | $260.21 Million | +2.80pp |
| 2017-12-31 | 75.03% | $113.85 Million | $151.74 Million | +42.64pp |
| 2016-12-31 | 32.39% | $4.00 Million | $12.34 Million | -24.78pp |
| 2013-12-31 | 57.18% | $10.40 Million | $18.19 Million | +29.32pp |
| 2012-12-31 | 27.85% | $5.27 Million | $18.92 Million | -- |
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more